EMBL begins partnership with Polish centre of excellence for neural plasticity and brain disorders
EMBL has signed a partnership agreement with BRAINCITY, a new Centre of Excellence for Neural Plasticity and Brain Disorders, in Poland. EMBL partnerships are close cooperative affiliations with national institutes in EMBL member states. This is EMBL’s twelfth partnership and furthers EMBL’s aim to create a network of international centres of scientific excellence and advanced training.
BRAINCITY, established as an independent unit at the Nencki Institute of Experimental Biology in Warsaw, will build on the Nencki Institute’s strong track record in neurobiological research, as well as on EMBL’s internationally recognised expertise in life science research and training, including specific expertise in neurobiology and epigenetics. Research at BRAINCITY will focus on the understanding and use of complex neuroplasticity for combating diseases, while closely collaborating with scientific, clinical and industry partners. BRAINCITY has been awarded funding of €9 million for a five-year period by the Foundation for Polish Science.
This latest partnership follows swiftly on Poland’s accession in February as EMBL’s 26th member state. “BRAINCITY is a key addition to the partnership network for EMBL, as we look towards Poland for exchange of scientific excellence and collaboration in groundbreaking research,” says Silke Schumacher, EMBL Director of International Relations, who leads the EMBL Partnership Programme. “We are also very excited to be able to implement the partnership immediately after Polish accession to EMBL, which is a result of excellent collaboration with the Nencki Institute.”
To study the effect of commonly used drugs on bacterial envelopes, EMBL scientists applied a biochemical assay using a colour reaction. The deeper the red, the stronger the disruptive effect of the drug.